Table 2.

Percentage of Low, Intermediate and High Baseline Serum Trough Levels for Each TNFi in Patients Categorized as Non-Responders or in Remission/Low Disease Activity at Baseline (A) as Well as After Two Years Follow-Up (B)

A	Low Trough Level		Intermediate Trough Level	High Trough Level
Infliximab (n=67)	<1 mg/L (n=12)		1–7 mg/L(n=38)	> 7 mg/L(n=17)
Remission/low disease activity, n (%)	9 (13)		36 (54)	17 (25)
Non-responders, n (%)	3 (4)		2 (3)	0 (0)
Adalimumab (n=63)	<1 mg/L (n=4)		1–8 mg/L (n=27)	>8 mg/L (n=32)
Remission/low disease activity, n (%)	3 (5)		25 (41)	32 (50)
Non-responders, n (%)	1 (2)		2 (3)	0 (0)
Etanercept (n=137)	<1 mg/L (n=9)		1–3 mg/L (n=108)	>3 mg/L (n=20)
Remission/low disease activity, n (%)	4 (3)		99 (72)	14 (10)
Non-responders, n (%)	5 (4)		9 (6)	6 (4)
Golimumab (n=39)	<0.5 mg/L (n=20)		0.5–3 mg/L (n=17)	>3 mg/L (n=2)
Remission/low disease activity, n (%)	19 (49)		16 (41)	2 (5)
Non-responders, n (%)	1 (3)		1 (3)	0 (0)
B	Low Trough Level		Intermediate Trough Level	High Trough Level
Infliximab (n=67)	<1 mg/L (n=16)		1–7 mg/L(n=37)	> 7 mg/L(n=14)
Remission/low disease activity, n (%)	2 (3)		27 (40)	11 (16)
Treatment failure, n (%)	14 (21)		10 (15)	3 (4)
Adalimumab (n=63)	<1 mg/L (n=4)		1–8 mg/L (n=38)	>8 mg/L (n=21)
Remission/low disease activity, n (%)	1 (2)		30 (48)	15 (24)
Treatment failure, n (%)	3 (5)		8 (13)	6 (10)
Etanercept(n=137)	<1 mg/L (n=10)		1–3 mg/L (n=66)	>3 mg/L (n=61)
Remission/low disease activity, n (%)	2 (1)		43 (32)	45 (33)
Treatment failure, n (%)	8 (6)		23 (17)	16(12)
Golimumab (n=39)	<0.5 mg/L (n=21)		0.5–3 mg/L (n=16)	>3 mg/L (n=2)
Remission/low disease activity, n (%)	17 (44)		13 (33)	0 (0)
Treatment failure, n (%)	4 (10)		3 (8)	2 (5)

Abbreviation: TNFi, TNF inhibitor.